Tibet AIM Pharm. Inc.

002826

CNE100002C39

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 17/05/2024 am IST			5-day change	1st Jan Change
9.27 ^CNY	-0.32%		+1.42%	-21.90%

26/04	Tibet AIM Pharm. Inc. Proposes Final Cash Dividend for 2023	CI
25/04	Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Tibet AIM Pharm. Inc. Approves the Election of Non-Independent Directors, Independent Directors and Non-Employee Supervisors

September 15, 2021 at 01:08 am IST

Tibet AIM Pharm. Inc. announced at its extraordinary general meeting held on September 13, 2021 approves the election of non-independent directors, independent directors and non-employee supervisors. The non-independent are Peng Hui, Zhou Zhan, Xu Ke, Zhang Yu and independent directors as Hu Ming, Xiao Xinggang and Feng Lan. The non-employee supervisors are Li Ling and Wang Zhongbin.

Latest news about Tibet AIM Pharm. Inc.

Tibet AIM Pharm. Inc. Proposes Final Cash Dividend for 2023	27/04	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Tranche Update on Tibet AIM Pharm. Inc.'s Equity Buyback Plan announced on October 30, 2023.	02/04	CI
Tranche Update on Tibet AIM Pharm. Inc.'s Equity Buyback Plan announced on October 30, 2023.	02/01	CI
Tibet AIM Pharm. Inc. announces an Equity Buyback for CNY 100 million worth of its shares.	29/23/29	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	29/23/29	CI
Tibet AIM Pharm. Inc. authorizes a Buyback Plan.	26/23/26	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	22/23/22	CI
Tibet AIM Pharm. Inc. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 07 July 2023	01/23/01	CI
Tibet AIM Pharm. Inc. Approves Cash Dividend for 2022	20/23/20	CI
Tibet Aim Pharm. Inc. Proposes Final Cash Dividend for the Year 2022	28/23/28	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/23/17	CI
Tibet Aim Pharm Chairman Resigns; Successor Named	13/23/13	MT
Tibet Aim Pharm Unit to Buy 21% Stake in US Medtech Firm Pier 88 Health for $6 Million	13/23/13	MT
Tibet AIM Pharm. Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/22/27	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	24/22/24	CI
Tibet Aim Pharm. Inc. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares) for the Year 2021, Payable on 8 July 2022	02/22/02	CI
Tibet AIM Pharm. Inc. Approves 2021 Profit Distribution Plan	20/22/20	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	27/22/27	CI
Tibet AIM Pharm. Inc. Proposes Final Cash Dividend for the Year 2021	23/22/23	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	08/22/08	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021	24/21/24	CI
Tibet AIM Pharm. Inc. Approves the Election of Non-Independent Directors, Independent Directors and Non-Employee Supervisors	15/21/15	CI
Tibet Aim Pharm. Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	25/21/25	CI

Chart Tibet AIM Pharm. Inc.

Duration

Period

More charts

Company Profile

TIBET AIM PHARM INC is a China-based company principally engaged in the research, design, manufacture and distribution of chemical drugs and Chinese patent medicine. The Companyâs products include self-manufacturing medicine and third-party medicine. Self-manufacturing medicine includes miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, as well as domperidone tablets, among others. Its third-party medicine includes gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, as well as carbetocin injection. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TIBET AIM PHARM. INC.	-21.90%	240M
ELI LILLY AND COMPANY	+32.09%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.34%	371B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+7.39%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.49%	169B

Other Pharmaceuticals